Molecular characterization of breast cancer cell response to metabolic drugs

Area of Science:

• Oncology
• Metabolic pathways
• Cancer biology

Background:

• Metabolic reprogramming is a key feature of cancer.
• Breast cancer subtypes exhibit distinct metabolic profiles, suggesting targeted drug potential.
• Metabolic inhibitors offer a promising avenue for cancer therapy.

Purpose of the Study:

• To investigate the heterogeneous response of breast cancer cell lines to metformin and rapamycin.
• To characterize the genetic and molecular underpinnings of differential drug responses.
• To explore the utility of integrated multi-omics and modeling approaches for understanding drug mechanisms.

Main Methods:

• Treatment of breast cancer cell lines with metformin and rapamycin.
• SNP genotyping and mass spectrometry-based proteomics for molecular characterization.
• Probabilistic graphical models for protein expression analysis and flux balance analysis (FBA) for metabolic modeling.

Main Results:

• Observed heterogeneous responses to metformin and rapamycin, including cell cycle disruption.
• Identified differential protein expression patterns and their impact on biological processes like transcription.
• FBA correlated predicted growth rates with cell viability and suggested increased reactive oxygen species enzymes with metformin.
• Proposed a novel method for assessing pathway-level flux differences.

Conclusions:

• Integrated multi-omics and computational modeling provide complementary insights into drug response.
• Drug responses targeting cancer metabolism are complex and subtype-dependent.
• Findings support the development of targeted metabolic therapies and elucidate their mechanisms of action.